In­dia’s Lupin bags Sym­bio­mix and its new­ly ap­proved an­tibi­ot­ic for $150M-plus

7 years ago
Deals

Deer­field com­mits $50M-plus to trans­la­tion­al drug R&D at the Broad

7 years ago
Financing

Am­gen catch­es a break as FDA re­jects Neu­las­ta knock­off; Zaf­gen gets a new CEO as Hugh­es moves to top sci­ence job

7 years ago
News Briefing

Gi­ant Mer­ck bud­dies up with lit­tle KalVista on lead drug, ig­nit­ing stock with a $760M deal

7 years ago
Pharma

Ab­b­Vie jumps on the on­colyt­ics band­wag­on, em­brac­ing Turn­stone in new col­lab­o­ra­tion

7 years ago
R&D
Pharma

Eli Lil­ly con­cedes a PhI­II flop for abe­maci­clib as break­out strat­e­gy floun­ders

7 years ago
R&D

Spark Ther­a­peu­tics faces a grilling as FDA pon­ders a pi­o­neer­ing OK for gene ther­a­py

7 years ago
Pharma
Cell/Gene Tx

Ab­bas Hus­sain swings from top GSK phar­ma post to pow­er­house Chi­nese pri­vate eq­ui­ty play­er C-Bridge

7 years ago
People
Financing

Biotech sci­en­tist/en­tre­pre­neur Saurabh Sa­ha makes an un­usu­al re­turn to the arms of a big — and ex­ces­sive­ly dis­creet ...

7 years ago
People
R&D

Third Rock-backed Al­lena looks to spring­board a $92M IPO off of a failed PhI­Ib

7 years ago
Financing

Flex­ion nabs FDA OK for its po­ten­tial block­buster os­teoarthri­tis drug, trig­ger­ing new buy­out buzz

7 years ago
Pharma

As­traZeneca’s next big can­cer drug linked to fal­si­fied pre­clin­i­cal da­ta; Har­mo­ny rais­es $270M, nabs de­vel­op­ment ...

7 years ago
News Briefing

David Meek­er starts a new biotech chap­ter in his ca­reer; Sam Kulka­rni takes the helm at CRISPR

7 years ago
Peer Review

Third Rock, SV bankroll an­oth­er PhI/II for a new, im­proved and jab-free wet AMD drug

7 years ago
Financing

'Go­ing big': Mer­ck launch­es front­line PhI­II lung can­cer study for Keytru­da/Yer­voy com­bo

7 years ago
R&D

Fac­ing an ex­o­dus, EMA starts to line up temp re­place­ments as top staffers jump ship

7 years ago
Pharma

In a set­back, Bay­er, J&J say their big PhI­II sec­ondary stroke tri­al for Xarel­to failed

7 years ago
R&D

Al­ler­gan shows how you can de­stroy your rep and get mobbed by law­mak­ers in 4 easy steps

7 years ago
Bioregnum
Opinion

We've tak­en a big step for­ward at End­points News — and with your help, we'll make more strides

7 years ago
Editor's note

Sanofi/Re­gen­eron win a new tri­al on Pralu­ent patents; Bridge­Bio bankrolls $30M biotech start­up

7 years ago
News Briefing

Aca­dia adopts a new PhI­II game plan for 'break­through' med, dumps Alzheimer's PhII

7 years ago
R&D

Face­book bil­lion­aires Pe­ter Thiel and Sean Park­er back­ing a stealth im­munother­a­py biotech — re­port

7 years ago
Financing
Startups

Blue­bird’s gene ther­a­py shows promise in keep­ing lethal Loren­zo’s Oil dis­ease in check

7 years ago
R&D
Cell/Gene Tx

Armed with a $47M round, Gates-backed Vis­ter­ra aims at a PhI­Ib flu drug study

7 years ago
Financing
Startups
First page Previous page 853854855856857858859 Next page Last page
A service from the Financial Times